4 articles
AbbVie lowered its 2026 profit forecast to account for the $10.9 billion Apogee Therapeutics acquisition while beating Q2 earnings estimates on strong immunology drug sales.
US stocks traded mixed as oil prices eased following US-Iran war talks, while pharmaceutical giant AbbVie agreed to acquire Apogee Therapeutics in a $10.9 billion deal.
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion to strengthen its immunology pipeline ahead of patent expirations. The deal secures access to experimental drug zumilokibart for treating
US stock futures remained subdued as investors tracked US-Iran negotiations impacting oil prices. Meanwhile, AbbVie nears a $10.9 billion deal for Apogee Therapeutics amid broader market optimism driv
ChemBrief